3078683-57-2
3078683-57-2
Chemical Structure
LT-1339-553
- CAS. Nr.: 3078683-57-2
- Formula:C21H13F5N4O3
- Molecular Weight:464.34
InChIKey: XAIVUPIKSGFRJI-UHFFFAOYSA-N
SMILES: NC1=NOC2=C1C(C3=C(C(F)=C(C=C3)NC(NC4=CC(OC(F)(F)F)=CC=C4)=O)F)=CC=C2
Biological Activity: LT-1339-553 is a selective, orally active RIPK1 inhibitor with IC50 values of 4.32, 95.74 and 84.33 nM against RIPK1, RIPK2 and RIPK3, respectively. LT-1339-553 exerts anti-necroptotic activity by inhibiting the AKT/PI3K/NF-κB pathway and the IL-17 pathway. LT-1339-553 reduces liver injury, inflammatory responses and collagen deposition. LT-1339-553 can be used in studies related to schistosomiasis-induced liver fibrosis[1].
| Art. -Nr. | Produktname | Reinheit | Beschreibung | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
LT-1339-553 | LT-1339-553 is a selective, orally active RIPK1 inhibitor with IC50 values of 4.32, 95.74 and 84.33 nM against RIPK1, RIPK2 and RIPK3, respectively. LT-1339-553 exerts anti-necroptotic activity by inhibiting the AKT/PI3K/NF-κB pathway and the IL-17 pathway. LT-1339-553 reduces liver injury, inflammatory responses and collagen deposition. LT-1339-553 can be used in studies related to schistosomiasis-induced liver fibrosis. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
